Literature DB >> 9258068

C-met proto-oncogene expression in benign and malignant human renal tissues.

L L Pisters1, A K el-Naggar, W Luo, A Malpica, S H Lin.   

Abstract

PURPOSE: Hepatocyte growth factor/scatter factor (HGF/SF) is a potent mitogen to renal epithelial cells in vitro and in vivo. HGF/SF signals through its receptor which is coded by the c-met proto-oncogene. We hypothesized that altered expression of the HGF/SF receptor, c-met, may be involved in the pathogenesis of certain renal cell carcinomas. Our objectives were to 1) assess the presence and localization of c-met protein in benign and malignant human renal tissues, and 2) correlate the presence of c-met protein with renal carcinoma histological subtype, tumor stage and tumor grade.
MATERIALS AND METHODS: Immunohistochemical analysis of c-met protein was performed in 41 normal and malignant human renal samples.
RESULTS: c-met Immunostaining was detected in the normal kidney tissue in all 41 samples. In the normal kidney c-met immunostaining was limited to the cell membrane and/or cytoplasm of epithelial cells in specific tubular segments, including the proximal convoluted tubule, thin and thick limbs of the loop of Henle, and the collecting duct. The glomeruli, distal convoluted tubule and stroma were consistently negative for c-met staining. c-met Immunostaining was detected in 68% of renal cell carcinomas and was more common in higher nuclear grade cancers (p < 0.034).
CONCLUSIONS: The c-met receptor is present in specific tubular segments in the normal kidney and is frequently expressed in higher nuclear grade renal cancers, suggesting a role in renal carcinoma progression. Future studies should evaluate the biological significance of the HGF/ SF-c-met pathway in normal renal physiology, and renal cancer growth and progression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9258068     DOI: 10.1097/00005392-199709000-00009

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  15 in total

1.  Expression of the c-Met Proteins in Malignant Skin Cancers.

Authors:  Yoon-Jin Lee; Dae-Hyun Kim; Sang-Han Lee; Dong-Wook Kim; Hae-Seon Nam; Moon Kyun Cho
Journal:  Ann Dermatol       Date:  2011-02-28       Impact factor: 1.444

2.  c-Met in chromophobe renal cell carcinoma.

Authors:  Franziska Erlmeier; Philipp Ivanyi; Arndt Hartmann; Michael Autenrieth; Max Wiedemann; Wilko Weichert; Sandra Steffens
Journal:  Med Oncol       Date:  2016-12-29       Impact factor: 3.064

3.  MET expression in sporadic renal cell carcinomas.

Authors:  Jong Sun Choi; Mi-Kyung Kim; Jin Won Seo; Yoon-La Choi; Dong Hoon Kim; Yi Kyeong Chun; Young Hyeh Ko
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

Review 4.  The renal effects of ALK inhibitors.

Authors:  Hassan Izzedine; Rania Kheder El-Fekih; Mark A Perazella
Journal:  Invest New Drugs       Date:  2016-07-29       Impact factor: 3.850

5.  Understanding the natural biology of kidney cancer: implications for targeted cancer therapy.

Authors:  Tobias Klatte; Allan J Pantuck; Mark D Kleid; Arie S Belldegrun
Journal:  Rev Urol       Date:  2007

6.  Expression of hepatocyte growth factor and its receptor met in Wilms' tumors and nephrogenic rests reflects their roles in kidney development.

Authors:  Raisa Vuononvirta; Neil J Sebire; Boo Messahel; Nina Perusinghe; Jorge S Reis-Filho; Kathy Pritchard-Jones; Gordan M Vujanic; Chris Jones
Journal:  Clin Cancer Res       Date:  2009-03-24       Impact factor: 12.531

Review 7.  Origin of renal cell carcinomas.

Authors:  Manuel Valladares Ayerbes; Guadalupe Aparicio Gallego; Silvia Díaz Prado; Paula Jiménez Fonseca; Rosario García Campelo; Luis Miguel Antón Aparicio
Journal:  Clin Transl Oncol       Date:  2008-11       Impact factor: 3.405

8.  Mutant p53 cooperates with knockdown of endogenous wild-type p53 to disrupt tubulogenesis in Madin-Darby canine kidney cells.

Authors:  Yanhong Zhang; Wensheng Yan; Xinbin Chen
Journal:  PLoS One       Date:  2013-12-27       Impact factor: 3.240

9.  Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma.

Authors:  Patrick Schöffski; Vincente Guillem; Margarita Garcia; Fernando Rivera; Josep Tabernero; Martin Cullell; Jose Antonio Lopez-Martin; Patricia Pollard; Herlinde Dumez; Xavier Garcia del Muro; Luis Paz-Ares
Journal:  Mar Drugs       Date:  2009-03-05       Impact factor: 5.118

10.  Serum hepatocyte growth factor as an index of disease status of patients with colorectal carcinoma.

Authors:  T Fukuura; C Miki; T Inoue; K Matsumoto; H Suzuki
Journal:  Br J Cancer       Date:  1998-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.